Factor V Leiden: Should all women be screened prior to commencing the contraceptive pill

Blood Reviews

Volumn 13, Issue 1, 1999, Pages 8-13

  Walker, I D ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT;

CAUCASIAN; COST EFFECTIVENESS ANALYSIS; EUROPE; FEMALE; GENE MUTATION; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; INSURANCE; LUNG EMBOLISM; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0032895009     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(99)90019-X     Document Type: Article

References (22)

1. Bertina R M, Koeleman B P C, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
2. Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C - Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506.
3. Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698 3703.
4. Vandenbroucke J P, Koster T, Briet E, Reitsma P H, Bertina R M. Rosendaal F R. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453-1457.
5. Tait R C, Walker I D, Reitsma P H et al. Prevalence of protein C deficiency in the healthy population. Thrombosis and Haemostasis 1995; 73:87-93.
6. Miletich J P, Sherman I, Broze G. Absence of thrombosis in subjects heterozygous for protein C deficiency. New England Journal of Medicine 1987; 317:991-996.
7. Tait R C, Walker I D, Perry D J et al. Prevalence of antithrombin deficiency in the healthy population. British Journal of Haematology 1994; 87:106-112.
8. Ridker P M, Hennekens C H, Lindpaintner K, Stanpfer M J, Eisenberg P R, Miletich J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. New England Journal of Medicine 1995; 332: 912-917
9. Lensen R P, Rosendaal F R, Koster T et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88: 4205-4208.
10. Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with different progestogen components. Lancet 1995; 346: 1589-1593.
11. WHO Collaborative Study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
12. Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case control study. Transnational Research Group on Oral Contraceptives and the health of young women. British Medical Journal 1996; 312: 83-88.
13. Bloemenkamp K W M, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet 1995; 346: 1593-1596.
14. Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K W M, Rosendaal F R. Third generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. American Journal of Obstetrics and Gynaecology 1997; 177: 887-891.
15. Olivieri O, Friso S, Manzato F et al. Resistance to activated protein C in healthy women taking oral contraceptives. British Journal of Haematology 1995; 91: 465-470.
16. Henkens C M A, Bom V J J, Seinen A J, van der Meer J. Sensitivity to activated protein C:influence of oral contraceptives and sex. Thrombosis and Haemostasis 1995; 73: 402-404.
17. Rosing J, Tans G, Nokolaes A F et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second and third generation oral contraceptives. British Journal of Haematology 1997; 97: 233-238.
18. Rosendaal R F. Risk factors for venous thrombosis: prevalence, risk and interaction. Seminars in Haematology 1997; 34: 171-187.
19. Vandenbroucke J P, van der Meer F J M, Helmerhorst F M, Rosendaal F R. Factor V Leiden: should we screen oral contraceptive users and pregnant women? British Medical Journal 1996; 313: 1127-1130.
20. Carter C J. The natural history and epidemiology of venous thrombosis. Progress in Cardiovascular Diseases 1994; 36: 423-428.
21. Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpainter K, Hennekens C K. Factor V Leiden and the risk of recurrent idiopathic venous thrombosis. Circulation 1995; 92: 2800-2802.
22. Briet E, van der Meer F J M, Rosendaal F R, Houwing-Duistermaat J J, Houwelingen G C. The family history and inherited thrombophilia. British Journal of Haematology 1994; 87: 348-352